← 產業報告目錄
US Alzheimer's Disease Diagnostic Market Research Report Forecast to 2040
授權報價
| Single User Price | $2,950 USD |
| Multi User Licence (up to 10 users) | $3,950 USD |
| Enterprisewide Price (Global Site License) | $5,250 USD |
報告摘要
US Alzheimer's Disease Diagnostic Market Research Report Forecast to 2040
Market Overview
US Alzheimer's Disease Diagnostic market is anticipated to register a notable CAGR of 7.92% during the review period. Alzheimer's disease, often referred to simply as Alzheimer's, is a progressive and degenerative brain disorder that primarily affects cognitive functions, especially memory, thinking, and behavior. It is the most common cause of dementia in older adults. The disease is characterized by the accumulation of abnormal protein deposits, including beta-amyloid plaques and tau tangles, in the brain, which lead to the death of brain cells and the disruption of neural pathways.
The US Alzheimer’s disease diagnostic market is emerging due to Increasing prevalence of Alzheimer’s disease, growing aging population and raising awareness about Alzheimer's disease. Additionally, growth of telemedicine and remote monitoring technologies presents opportunities for Alzheimer's disease diagnostics market in the future. However, the high cost of diagnosis might hamper the market's growth in the forecast period.
Market Segmentation
Based on product, the market has been segmented into reagents & kits and equipment & accessories.
Based on the type, the market has been segmented into early onset Alzheimer disease and late onset Alzheimer disease.
Based on test type, the US Alzheimer’s disease diagnostic market has been segmented into genetic testing, brain imaging, neurological exams, mini mental state exam (MMSE), and others.
Based on end user, the US Alzheimer’s disease diagnostic market has been segmented into hospitals, and diagnostic laboratories, and others.
Major Players
The Key market players in the US Alzheimer's Disease Diagnostic market are Siemens, F. Hoffmann-La Roche Ltd, GE Healthcare, Fujirebio, QYNAPSE, and Koninklijke Philips N.V.
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 14
2 MARKET INTRODUCTION 16
2.1 DEFINITION 16
2.2 SCOPE OF THE STUDY 16
2.3 RESEARCH OBJECTIVE 16
2.4 MARKET STRUCTURE 17
3 RESEARCH METHODOLOGY 18
3.1 OVERVIEW 18
3.2 DATA FLOW 19
3.2.1 DATA MINING PROCESS 20
3.3 PURCHASED DATABASE: 21
3.4 SECONDARY SOURCES: 22
3.4.1 SECONDARY RESEARCH DATA FLOW: 23
3.5 PRIMARY RESEARCH: 24
3.5.1 PRIMARY RESEARCH DATA FLOW: 25
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 26
3.6.1 REVENUE ANALYSIS APPROACH 26
3.7 DATA FORECASTING 27
3.7.1 DATA FORECASTING TECHNIQUE 27
3.8 DATA MODELING 28
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 28
3.8.2 DATA MODELING: 29
3.9 TEAMS AND ANALYST CONTRIBUTION 31
4 MARKET DYNAMICS 33
4.1 INTRODUCTION 33
4.2 DRIVERS 34
4.2.1 INCREASING PREVALENCE OF ALZHEIMER’S DISEASE 34
4.2.2 GROWING AGING POPULATION 34
4.2.3 RAISING AWARENESS ABOUT ALZHEIMER'S DISEASE 35
4.3 RESTRAINTS 36
4.3.1 HIGH COST OF DIAGNOSIS 36
4.4 OPPORTUNITY 37
4.4.1 GROWTH OF TELEMEDICINE AND REMOTE MONITORING TECHNOLOGIES PRESENTS OPPORTUNITIES FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 37
5 MARKET FACTOR ANALYSIS 38
5.1 VALUE CHAIN ANALYSIS 38
5.1.1 R&D AND DESIGNING 39
5.1.2 MANUFACTURING 39
5.1.3 DISTRIBUTION, MARKETING, AND SALES 39
5.1.4 POST-SALES MONITORING 39
5.2 PORTER'S FIVE FORCES MODEL 40
5.2.1 BARGAINING POWER OF SUPPLIERS 40
5.2.2 BARGAINING POWER OF BUYERS 41
5.2.3 THREAT OF NEW ENTRANTS 41
5.2.4 THREAT OF SUBSTITUTES 41
5.2.5 INTENSITY OF RIVALRY 41
5.3 IMPACT ANALYSIS OF COVID-19 ON ALZHEIMER’S DISEASE DIAGNOSTIC MARKET 41
5.3.1 OVERVIEW 41
5.4 MARKET KEY TRENDS FOR ALZHEIMER'S DISEASE DIAGNOSTIC MARKET 42
5.5 ANALYSIS OF INTELLECTUAL PROPERTY (IP) & STARTUPS 42
5.5.1 INTELLECTUAL PROPERTY (IP) 42
5.5.2 STARTUPS 43
5.6 CHANGES IN HEALTHCARE POLICIES 43
5.7 CLINICAL DIAGNOSIS OF ALZHEIMER'S DISEASE 44
5.8 PROVIDER AND PAYER COVERAGE POLICIES FOR ALZHEIMER'S DISEASE DIAGNOSTICS 45
5.9 ALZHEIMER'S DISEASE PRE-DIAGNOSIS AND DIAGNOSIS IN THE US 45
5.10 ALZHEIMER'S DISEASE TREATMENT/ DISEASE MANAGEMENT AND MONITORING 46
6 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY PRODUCT 48
6.1 OVERVIEW 48
7 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY TYPE 51
7.1 OVERVIEW 51
8 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY TEST TYPE 54
8.1 OVERVIEW 54
9 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY END USER 58
9.1 OVERVIEW 58
10 COMPETITIVE LANDSCAPE 62
10.1 INTRODUCTION 62
10.2 MARKET SHARE ANALYSIS, 2022 63
10.3 COMPETITOR DASHBOARD 64
10.4 PUBLIC PLAYERS STOCK SUMMARY 65
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 65
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 66
10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 66
10.6.1 PARTNERSHIP 66
11 COMPANY PROFILES 67
11.1 SIEMENS 67
11.1.1 COMPANY OVERVIEW 67
11.1.2 FINANCIAL OVERVIEW 68
11.1.3 PRODUCTS OFFERED 69
11.1.4 KEY DEVELOPMENTS 70
11.1.5 SWOT ANALYSIS 70
11.1.6 KEY STRATEGIES 71
11.2 F. HOFFMANN-LA ROCHE LTD 72
11.2.1 COMPANY OVERVIEW 72
11.2.2 FINANCIAL OVERVIEW 73
11.2.3 PRODUCTS OFFERED 73
11.2.4 KEY DEVELOPMENTS 74
11.2.5 SWOT ANALYSIS 74
11.2.6 KEY STRATEGIES 75
11.3 GE HEALTHCARE 76
11.3.1 COMPANY OVERVIEW 76
11.3.2 FINANCIAL OVERVIEW 77
11.3.3 PRODUCTS OFFERED 77
11.3.4 KEY DEVELOPMENTS 78
11.3.5 SWOT ANALYSIS 78
11.3.6 KEY STRATEGIES 79
11.4 KONINKLIJKE PHILIPS N.V. 80
11.4.1 COMPANY OVERVIEW 80
11.4.2 FINANCIAL OVERVIEW 81
11.4.3 PRODUCTS OFFERED 81
11.4.4 KEY DEVELOPMENTS 82
11.4.5 SWOT ANALYSIS 83
11.4.6 KEY STRATEGIES 83
11.5 BMG LABTECH 84
11.5.1 COMPANY OVERVIEW 84
11.5.2 FINANCIAL OVERVIEW 84
11.5.3 PRODUCTS OFFERED 84
11.5.4 KEY DEVELOPMENTS 84
11.5.5 KEY STRATEGIES 85
11.6 BIOASSAY SYSTEMS 86
11.6.1 COMPANY OVERVIEW 86
11.6.2 FINANCIAL OVERVIEW 86
11.6.3 PRODUCTS OFFERED 86
11.6.4 KEY DEVELOPMENTS 87
11.6.5 SWOT ANALYSIS 87
11.6.6 KEY STRATEGIES 87
11.7 SCIENCELL RESEARCH LABORATORIES, INC 88
11.7.1 COMPANY OVERVIEW 88
11.7.2 FINANCIAL OVERVIEW 88
11.7.3 PRODUCTS OFFERED 88
11.7.4 KEY DEVELOPMENTS 88
11.7.5 KEY STRATEGIES 89
11.8 FUJIREBIO 90
11.8.1 COMPANY OVERVIEW 90
11.8.2 FINANCIAL OVERVIEW 90
11.8.3 PRODUCTS OFFERED 90
11.8.4 KEY DEVELOPMENTS 91
11.8.5 KEY STRATEGIES 91
11.9 QUANTERIX 92
11.9.1 COMPANY OVERVIEW 92
11.9.2 FINANCIAL OVERVIEW 92
11.9.3 PRODUCTS OFFERED 92
11.9.4 KEY DEVELOPMENTS 93
11.9.5 KEY STRATEGIES 93
11.10 QYNAPSE 94
11.10.1 COMPANY OVERVIEW 94
11.10.2 FINANCIAL OVERVIEW 94
11.10.3 PRODUCTS OFFERED 94
11.10.4 KEY DEVELOPMENTS 95
11.10.5 KEY STRATEGIES 95
12 DATA CITATIONS 96
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 29
TABLE 2 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2019–2040 (USD MILLION) 49
TABLE 3 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY TYPE, 2019–2040 (USD MILLION) 52
TABLE 4 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY TEST TYPE, 2019–2040 (USD MILLION) 56
TABLE 5 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, FOR BRAIN IMAGING, BY TYPE, 2019–2040 (USD MILLION) 56
TABLE 6 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY END USER, 2019–2040 (USD MILLION) 59
TABLE 7 PUBLIC PLAYERS STOCK SUMMARY 65
TABLE 8 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 65
TABLE 9 PRODUCT LAUNCH/PRODUCT APPROVAL 66
TABLE 10 PARTNERSHIP 66
TABLE 11 SIEMENS: PRODUCTS OFFERED 69
TABLE 12 SIEMENS: KEY DEVELOPMENTS 70
TABLE 13 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 73
TABLE 14 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 74
TABLE 15 GE HEALTHCARE: PRODCUTS OFFERED 77
TABLE 16 KONINKLIJKE PHILIPS N.V.: PRODCUTS OFFERED 81
TABLE 17 KONINKLIJKE PHILIPS N.V.: KEY DEVELOPMENTS 82
TABLE 18 BMG LABTECH: PRODCUTS OFFERED 84
TABLE 19 BIOASSAY SYSTEMS: PRODUCTS OFFERED 86
TABLE 20 SCIENCELL RESEARCH LABORATORIES, INC: PRODUCTS OFFERED 88
TABLE 21 FUJIREBIO: PRODCUTS OFFERED 90
TABLE 22 FUJIREBIO: KEY DEVELOPMENTS 91
TABLE 23 QUANTERIX: PRODCUTS OFFERED 92
TABLE 24 QYNAPSE: PRODCUTS OFFERED 94
TABLE 25 QYNAPSE: KEY DEVELOPMENTS 95
LIST OF FIGURES
FIGURE 1 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET: STRUCTURE 17
FIGURE 2 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 33
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2040) 35
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 36
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET 40
FIGURE 6 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, PRODUCT SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 48
FIGURE 7 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2022 & 2040 (USD MILLION) 49
FIGURE 8 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET SHARE (%), BY PRODUCT, 2022 50
FIGURE 9 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, TYPE SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 51
FIGURE 10 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY TYPE, 2022 & 2040 (USD MILLION) 52
FIGURE 11 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET SHARE (%), BY TYPE, 2022 53
FIGURE 12 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, TEST TYPE, SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 55
FIGURE 13 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY TEST TYPE, 2022 & 2040 (USD MILLION) 55
FIGURE 14 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET SHARE (%), BY TEST TYPE, 2022 57
FIGURE 15 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, END USER SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 58
FIGURE 16 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY END USER, 2022 & 2040 (USD MILLION) 59
FIGURE 17 US ALZHEIMER’S DISEASE DIAGNOSTIC MARKET SHARE (%), BY END USER, 2022 60
FIGURE 18 US ALZHEIMER’S DISEASE DIAGNOSTICS MARKET PLAYERS: COMPETITIVE ANALSIS, 2022 63
FIGURE 19 COMPETITOR DASHBOARD: US ALZHEIMER’S DISEASE DIAGNOSTICS MARKET 64
FIGURE 20 SIEMENS: FINANCIAL OVERVIEW SNAPSHOT 68
FIGURE 21 SIEMENS: SWOT ANALYSIS 70
FIGURE 22 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 73
FIGURE 23 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 74
FIGURE 24 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT 77
FIGURE 25 GE HEALTHCARE: SWOT ANALYSIS 78
FIGURE 26 KONINKLIJKE PHILIPS N.V.: FINANCIAL OVERVIEW SNAPSHOT 81
FIGURE 27 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS 83
FIGURE 28 BIOASSAY SYSTEMS: SWOT ANALYSIS 87
提及公司
SiemensF. Hoffmann-La Roche LtdGE HealthcareFujirebioQYNAPSEand Koninklijke Philips N.V.
同分類最新報告（醫療器材）
查看醫療器材全部報告 →
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們